Advertisement

 

 

Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach.

Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach.
Author Information (click to view)

Beccari AR, Gemei M, Monte ML, Menegatti N, Fanton M, Pedretti A, Bovolenta S, Nucci C, Molteni A, Rossignoli A, Brandolini L, Taddei A, Za L, Liberati C, Vistoli G,


Beccari AR, Gemei M, Monte ML, Menegatti N, Fanton M, Pedretti A, Bovolenta S, Nucci C, Molteni A, Rossignoli A, Brandolini L, Taddei A, Za L, Liberati C, Vistoli G, (click to view)

Beccari AR, Gemei M, Monte ML, Menegatti N, Fanton M, Pedretti A, Bovolenta S, Nucci C, Molteni A, Rossignoli A, Brandolini L, Taddei A, Za L, Liberati C, Vistoli G,

Advertisement

Scientific reports 2017 09 087(1) 10999 doi 10.1038/s41598-017-11194-0
Abstract

Transient receptor potential melastatin 8 (TRPM8), a nonselective cation channel, is the predominant mammalian cold temperature thermosensor and it is activated by cold temperatures and cooling compounds, such as menthol and icilin. Because of its role in cold allodynia, cold hyperalgesia and painful syndromes TRPM8 antagonists are currently being pursued as potential therapeutic agents for the treatment of pain hypersensitivity. Recently TRPM8 has been found in subsets of bladder sensory nerve fibres, providing an opportunity to understand and treat chronic hypersensitivity. However, most of the known TRPM8 inhibitors lack selectivity, and only three selective compounds have reached clinical trials to date. Here, we applied two virtual screening strategies to find new, clinics suitable, TRPM8 inhibitors. This strategy enabled us to identify naphthyl derivatives as a novel class of potent and selective TRPM8 inhibitors. Further characterization of the pharmacologic properties of the most potent compound identified, compound 1, confirmed that it is a selective, competitive antagonist inhibitor of TRPM8. Compound 1 also proved itself active in a overreactive bladder model in vivo. Thus, the novel naphthyl derivative compound identified here could be optimized for clinical treatment of pain hypersensitivity in bladder disorders but also in different other pathologies.

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × two =

[ HIDE/SHOW ]